To the Editor: Multisystem inflammatory syndrome–children (MIS-C) is a newly recognized spectrum of disease manifestations in children associated with COVID-19 infection [1]. This letter aims to describe the clinicotherapeutic profile of MIS-C COVID-19 cases admitted at a tertiary hospital in Delhi-NCR. We observed 12 cases with a median age of 6.5 y (9 male; 3 female). Eleven showed seropositivity for COVID-19 while 1 had a positive COVID-19 RT-PCR. As proposed by Gupta et al. [2], cases were divided into 3 groups: febrile inflammatory state (5 cases), Kawasaki-like illness (3 cases), and toxic shock syndrome-like classical MIS-C (4 cases). Fever was present in all cases. Gastrointestinal system was the most commonly affected system with vomiting being the most common symptom. Cardiovascular symptoms were seen in 6 (50%) cases. Three children showed neurological impairment with 1 case each of refractory status epilepticus, acute disseminated encephalomyelitis (ADEM), and necrotizing encephalopathy. Respiratory system was involved in 5 (41.6%) children. Elevated CRP was noted in all children, elevated ferritin in 8 (66.7%), elevated D-dimer in 10 (83.3%), and deranged PT/INR/aPTT in 4 (33%) cases. High Pro-BNP was seen in 8; of which, 4 showed deranged ejection fraction. Consolidation and/or pleural effusion was seen in 7 (58.3%) cases. All children received steroids, while 7 children received IVIg. LMWH and aspirin were given to children with raised D-dimer and Kawasaki-like illness, respectively. Six children needed vasopressor support. Three patients died during the course of the disease while 1 suffered morbidity in the form of hemiparesis. Rest all were discharged after full recovery of presenting symptoms.
MIS-C COVID-19 should be considered in cases with longstanding fever and/or multisystem involvement. In the absence of standardized guidelines, clinicians are often missing mild cases or misdiagnosing the presentation [3]. It also emphasizes the need for further studies in this field.
Declarations
Conflict of Interest
None.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Health advisory on multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019. In:Centers for Disease Control and Prevention (CDC).2019. Available at https://emergency.cdc.gov/han/2020/han00432.asp?deliveryNameUSCDC_511-DM28431. Accessed on 1 Feb 2021.
- 2.Gupta D, Simalti A, Gupta N, Bhardwaj P, Bansal A, Sachdev A. Management principles of COVID-19 in Adolescents and Children. Indian J Adolesc Med (Special Section). 2020;1:47–57.
- 3.Levin M. Childhood multisystem inflammatory syndrome-a new challenge in the pandemic. N Engl J Med. 2020;383:393–395. doi: 10.1056/NEJMe2023158. [DOI] [PMC free article] [PubMed] [Google Scholar]